Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aligos Therapeutics (ALGS) Leases (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Leases readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, Leases fell 37.77% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 37.77% decrease, with the full-year FY2025 number at $3.1 million, down 37.77% from a year prior.
  • Leases hit $3.1 million in Q4 2025 for Aligos Therapeutics, down from $3.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $8.8 million in Q4 2021 to a low of $3.1 million in Q4 2025.
  • Median Leases over the past 5 years was $6.8 million (2021), compared with a mean of $6.4 million.
  • Biggest five-year swings in Leases: increased 27.36% in 2021 and later crashed 37.77% in 2025.
  • Aligos Therapeutics' Leases stood at $8.8 million in 2021, then fell by 12.41% to $7.7 million in 2022, then decreased by 14.8% to $6.6 million in 2023, then decreased by 24.32% to $5.0 million in 2024, then tumbled by 37.77% to $3.1 million in 2025.
  • The last three reported values for Leases were $3.1 million (Q4 2025), $3.6 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.